Why the study?
The purpose was to analyze associative studies of CYP3A4 / 5 and ABCB1 genes and search for new candidate genes reflecting the efficacy and safety of edoxaban.
This review highlights the pharmacokinetic profile of edoxaban and identifies CES1, CYP3A4/5, and ABCB1 as key candidate genes for its metabolism, emphasizing the need for further pharmacogenetic studies in clinical practice.
Pharmacogenetic associations for edoxaban remain associative; leaves open validation before any dosing implications.
Edoxaban is a new generation of oral anticoagulant; it is selective, direct and reversible inhibitor of activated blood coagulation factor X (F Xa), serine protease responsible for thrombin formation. Edoxaban is used to prevent stroke in non-valvular atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism. The purpose of the review is to analyze the associative studies of OHB of CYP3A4 / 5 and ABCB1 genes, as well as to search for new candidate genes reflecting the efficacy and safety of edoxaban. The search for full-text publications in Russian and English over the past two decades was carried out in eLibrary, PubMed, Web of Science, OMIM databases using the following keywords: edoxaban, pharmacokinetics, pharmacogenetics, efficacy, and safety. The review covers pharmacokinetics of edoxaban, as well as pharmacogenetic features of the drug metabolism in details. Candidate genes influencing concentration of edoxaban are genes encoding key enzymes of its metabolism – CES1, CYP3A4 / 5, ABCB1, and, to a lesser extent, SLCO1B1. By present day, numerous NVS of candidate genes have been identified. They potentially affect pharmacokinetics of edoxaban, but their role in real clinical practice requires further study
No takes yet. Share an insight, caveat, or question.
Savinova et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: